Cited by 444Substance Abuse Treatment and OutcomesAlcohol Consumption and Health EffectsAlcoholism and Thiamine Deficiency

The DOI matches its Crossref record; 43 of the 43 references it cites were found in a registry or an index.

Pharmacological Treatment of Alcohol Dependence: A Review of the Evidence

Garbutt, James C., West, Suzanne L., Carey, Timothy S., Lohr, Kathleen N., Crews, Fulton T.·1999·JAMA

DOI 10.1001/jama.281.14.1318

Open this paper in CoChat — free account

Abstract

CONTEXT: Alcoholism affects approximately 10% of Americans at some time in their lives. Treatment consists of psychosocial interventions, pharmacological interventions, or both, but which drugs are most effective at enhancing abstinence and preventing relapse has not been systematically reviewed. OBJECTIVE: To evaluate the efficacy of 5 categories of drugs used to treat alcohol dependence--disulfiram, the opioid antagonists naltrexone and nalmefene, acamprosate, various serotonergic agents (including selective serotonergic reuptake inhibitors), and lithium. DATA SOURCES: Reports of randomized controlled trials, nonrandomized trials, and other study designs in English, French, and German identified from multiple searches of MEDLINE, EMBASE, and specialized databases; hand searching bibliographies of review articles; searches for unpublished literature; and discussions with investigators in the field. STUDY SELECTION: We included all studies on alcohol-dependent human subjects aged 18 years or older from all inpatient and outpatient settings between 1966 and December 1997 that met our inclusion criteria. DATA EXTRACTION: We abstracted the following information: study design and blinding, diagnostic instrument and severity assessment, drug interventions and cointerventions, demographic and comorbidity details about patients, compliance, and numerous outcome measures (eg, relapse, return to drinking, drinking or nondrinking days, time to first drink, alcohol consumed per unit of time, craving). We graded quality of the individual articles (scale, 0-100) independently from the strength of evidence for each drug class (A, strong and consistent evidence of efficacy in studies of large size and/or high quality; B, mixed evidence of efficacy; C, evidence of lack of efficacy; and I, insufficient evidence). DATA SYNTHESIS: Of 375 articles evaluated, we abstracted and analyzed data from 41 studies and 11 follow-up or subgroup studies. Naltrexone (grade A) reduces the risk of relapse to heavy drinking and the frequency of drinking compared with placebo but does not substantially enhance abstinence, ie, avoidance of any alcohol consumption. Acamprosate (grade A, from large-scale studies in Europe) reduces drinking frequency, although its effects on enhancing abstinence or reducing time to first drink are less clear. Controlled studies of disulfiram (grade B) reveal a mixed outcome pattern--some evidence that drinking frequency is reduced but minimal evidence to support improved continuous abstinence rates. The limited data on serotonergic agents were not very promising (grade I), although most studies were confounded by high rates of comorbid mood disorders. Lithium lacks efficacy (grade C) in the treatment of primary alcohol dependence. CONCLUSIONS: Recent reports documenting that naltrexone and acamprosate are more effective than placebo in the treatment of alcoholism justify clinical interest in use of these medications for alcohol-dependent patients. Use of disulfiram is widespread but less clearly supported by the clinical trial evidence; however, targeted studies on supervised administration of disulfiram may be warranted. Use of existing serotonergic agents or lithium for patients with primary alcohol dependence does not appear to be supported by the efficacy data available at this time; these medications may still have a positive effect in patients with coexisting psychiatric disorders.

Integrity signals

Registry

Crossref · 10.1001/jama.281.14.1318

Cites

43 of 43 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Actual causes of death in the United States
McGinnis, J. M. (1993) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1993.03510180077038 · Cited by 5,480
Naltrexone in the Treatment of Alcohol Dependence
Volpicelli, J. R. (1992) · Archives of General Psychiatry · doi:10.1001/archpsyc.1992.01820110040006 · Cited by 1,828
Naltrexone and Coping Skills Therapy for Alcohol Dependence
O’Malley, S. S. (1992) · Archives of General Psychiatry · doi:10.1001/archpsyc.1992.01820110045007 · Cited by 1,476
Pharmacological Management of Alcohol Withdrawal: A Meta-analysis and Evidence-Based Practice Guideline
Mayo-Smith, M. F. (1997) · JAMA · doi:10.1001/jama.278.2.144 · Cited by 434
Naltrexone and Alcohol Dependence
Volpicelli, J. R. (1997) · Archives of General Psychiatry · doi:10.1001/archpsyc.1997.01830200071010 · Cited by 411
Disulfiram Treatment of Alcoholism
Chick, J., Gough, K. A., Falkowski, W., Kershaw, P. W., Hore, B. D., Mehta, B. M., Ritson, B., Ropner, R., & Torley, D. (1992) · The British Journal of Psychiatry · doi:10.1192/bjp.161.1.84 · Cited by 369
Fluoxetine in Depressed Alcoholics
Cornelius, J. R. (1997) · Archives of General Psychiatry · doi:10.1001/archpsyc.1997.01830200024004 · Cited by 356
Comparison of acamprosate and placebo in long-term treatment of alcohol dependence
Whitworth, A. B., OBERBAUER, H., Fleischhacker, W. W., Lesch, O., Walter, H., Nimmerrichter, A., Platz, T., Fischer, F., & Potgieter, A. S. (1996) · The Lancet · doi:10.1016/s0140-6736(96)91682-7 · Cited by 319
Effect of naltrexone on alcohol “high” in alcoholics
(1995) · American Journal of Psychiatry · doi:10.1176/ajp.152.4.613 · Cited by 308
Prevalence of DSM-IV Alcohol Abuse and Dependence: United States, 1992.
Grant, B. F., Harford, T. C., Dawson, D. A., Chou, P. S., Dufour, M. C., & Pickering, R. P. (1994) · PubMed Central · Cited by 287

Show all 43 references

Sorted by citations

Items 201–300 of 443

Substance Use Disorder
Swimmer, K. R., & Sandelich, S. (2023) · Emergency Medicine Clinics of North America · doi:10.1016/j.emc.2023.06.023 · Cited by 20
The role of affective temperament as a predictor of relapse in alcohol dependence
Paulino, S., Pombo›, S., Ismail, F., Figueira, M. L., & Lesch, O. (2017) · Personality and Mental Health · doi:10.1002/pmh.1373 · Cited by 20
Gamma‐hydroxybutyric acid in alcohol preference, dependence and withdrawal
Colombo, G., & Gessa, G. L. (2000) · Addiction Biology · doi:10.1111/j.1369-1600.2000.tb00207.x · Cited by 20
“Historically, however, pharmacotherapies were focused mainly on relieving the symptomatology of alcohol withdrawal syndrome; only recently have medications to help achieve and maintain abstinence and control alcohol craving been developed.(72,73) To date, three studies have assessed the efficacy of GHB on craving for…”
Background
Alcoholism and Substance Abuse
Warne, D. K. (2012) · Elsevier eBooks · doi:10.1016/b978-1-4377-1793-8.00065-0 · Cited by 20
Characterizing the Variation of Alcohol Cessation Pharmacotherapy in Primary Care
Bernstein, E. Y., Guo, N., Goto, T., & Rothberg, M. B. (2021) · Journal of General Internal Medicine · doi:10.1007/s11606-020-06454-1 · Cited by 19
HIV risk and prevention for non-injection substance users
Drumright, L. N., & Colfax, G. N. (2009) · Elsevier eBooks · doi:10.1016/b978-0-12-374235-3.00013-3 · Cited by 16
Low-dose prazosin alone and in combination with propranolol or naltrexone: effects on ethanol and sucrose seeking and self-administration in the P rat
Verplaetse, T. L., & Czachowski, C. L. (2015) · Psychopharmacology · doi:10.1007/s00213-015-3896-z · Cited by 19
“However, subsequent studies indicate that naltrexone is only modestly effective in reducing alcohol consumption (Kranzler and Van Kirk 2001) and does not increase abstinent rates among alcoholics (Garbutt et al. 1999).”
Background
Pharmacological approaches to the management of alcohol addiction.
Addolorato, G., Armuzzi, A., Gasbarrini, G., Lorenzi, G. D., Ancona, C., Abenavoli, L., Parente, A., Leggio, L., Capristo, E., Greco, A., et al. (2002) · PubMed · Cited by 18
Current progress in pharmacologic treatment strategies for alcohol dependence
Clapp, P. (2012) · Expert Review of Clinical Pharmacology · doi:10.1586/ecp.12.31 · Cited by 17
Associations of Alcohol Use Disorder, Alcohol Use, Housing, and Service Use in A Homeless Sample of 255 Individuals Followed over 2 Years
Asana, O. O., Ayvaci, E. R., Pollio, D. E., Hong, B. A., & North, C. S. (2018) · Substance Abuse · doi:10.1080/08897077.2018.1449169 · Cited by 15
Long-term outcome of in-patients with substance use disorders: A study from North India
Mattoo, S., Singh, S., Dutt, A., Chakrabarti, K., Nebhinani, N., Kumar, S., & Basu, D. (2008) · Indian Journal of Psychiatry · doi:10.4103/0019-5545.44750 · Cited by 17
“abstinence after detoxification but the effectiveness of these drugs remains doubtful as well,[7-9] and a combination”
Background
Alcohol Withdrawal Syndrome: Assessment and Treatment with the Use of the Clinical Institute Withdrawal Assessment for Alcohol-Revised
Puz, C. A., & Stokes, S. J. (2005) · Critical Care Nursing Clinics of North America · doi:10.1016/j.ccell.2005.04.001 · Cited by 17
“Disulfiram may reduce drinking days in alcoholdependent patients, but there is only minimal evidence that it facilitates abstinence [29].”
Background
When should clinicians switch treatments? An application of signal detection theory to two treatments for women with alcohol use disorders
Hildebrandt, T., McCrady, B. S., Epstein, E. E., Cook, S., & Jensen, N. (2010) · Behaviour Research and Therapy · doi:10.1016/j.brat.2010.03.001 · Cited by 17
Pharmacotherapy for Alcohol Use Disorders: Physicians’ Perceptions and Practices
Martinez, C. C. P., Vakkalanka, J. P., & Ait‐Daoud, N. (2016) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2016.00182 · Cited by 17
Treatment for alcohol related problems
Ritson, B. (2005) · BMJ · doi:10.1136/bmj.330.7483.139 · Cited by 16
The Addicted-Self Model: An Explanation of “Natural” Recovery?
Fiorentine, R., & Hillhouse, M. P. (2001) · Journal of Drug Issues · doi:10.1177/002204260103100203 · Cited by 17
Molecular Targets of Alcohol Action
Gorini, G., Bell, R. L., & Mayfield, R. D. (2011) · Progress in molecular biology and translational science · doi:10.1016/b978-0-12-385506-0.00007-7 · Cited by 16
The effect of acamprosate on alcohol and food craving in patients with alcohol dependence
Han, D. H., Lyool, I. K., Sung, Y. H., Lee, S. H., & Renshaw, P. F. (2008) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2007.09.014 · Cited by 16
Pharmacotherapeutic interventions in alcohol dependence
Sabri, R., & Drummond, C. (2004) · Psychiatry · doi:10.1383/psyt.3.1.40.30303 · Cited by 16
Global Mental Health 3 Treatment and prevention of mental disorders in low-income and middle-income countries
Patel, V., Araya, R., Chatterjee, S., Chisholm, D., Cohen, A., Silva, M. J. D., Hosman, C. M. H., McGuire, H., Rojas, G., & van Ommeren, M. (2007) · Cited by 15
Advances in the treatment of craving for alcohol and tobacco
Monti, P. M., & MacKillop, J. M. (2007) · Elsevier eBooks · doi:10.1016/b978-008044927-2/50060-2 · Cited by 15
In Situ Gel Incorporating Disulfiram Nanoparticles Rescues the Retinal Dysfunction via ATP Collapse in Otsuka Long–Evans Tokushima Fatty Rats
Deguchi, S., Ogata, F., Yamaguchi, M., Minami, M., Otake, H., Kanai, K., Kawasaki, N., & Nagai, N. (2020) · Cells · doi:10.3390/cells9102171 · Cited by 15
“DIS has been used as an anti-alcoholism drug in the clinic, and its long-term use is very safe and well-tolerated with few side effects [31].”
NHG-Standaard Problematisch alcoholgebruik
Meerkerk, G., Aarns, T., Dijkstra, R. H., Weisscher, P., Njoo, K. H., & Boomsma, L. (2009) · Bohn Stafleu van Loghum eBooks · doi:10.1007/978-90-313-6614-9_29 · Cited by 15
Medical Illness and Comorbidities in Drug Users: Implications for Addiction Pharmacotherapy Treatment
Draper, J. C., & McCance‐Katz, E. F. (2005) · Substance Use & Misuse · doi:10.1080/10826080500294775 · Cited by 15
“Both of these agents have shown clinical efficacy (Gatbutt et al., 1999).”
Background
Naloxone does not attenuate the locomotor effects of ethanol in FAST, SLOW, or two heterogeneous stocks of mice
Holstein, S. E., Pastor, R., Meyer, P., & Phillips, T. J. (2005) · Psychopharmacology · doi:10.1007/s00213-005-0066-8 · Cited by 14
“…experimental support as a therapeutic agent for alcoholism; Kranzler et al. 2000; Latt et al. 2002; O’Brien et al. 1996; O’Malley et al. 1992; Volpicelli et al. 1992; for review, see Garbutt et al. 1999) has also been found to significantly attenuate the locomotor stimulant effects of ethanol.”
Background
A randomized trial of low-dose gabapentin for post hospitalization relapse prevention in a Thai clinical sample of alcohol dependence
Chompookham, P., Rukngan, W., Nilaban, S., Suwanmajo, S., Yoosom, P., & Kalayasiri, R. (2018) · Psychiatry Research · doi:10.1016/j.psychres.2018.09.002 · Cited by 14
Therapeutic options and challenges for substances of abuse
Gardner, T. J., & Kosten, T. R. (2007) · Dialogues in Clinical Neuroscience · doi:10.31887/dcns.2007.9.4/tgardner · Cited by 13
Alcohol use disorders in women
Cyr, M. G., & McGarry, K. (2002) · Postgraduate Medicine · doi:10.3810/pgm.2002.12.1363 · Cited by 14
Adherence with naltrexone prescription advice in hospital outpatient alcohol rehabilitation programme
Feeney, G. F. X., Connor, J. P., Young, R. M., Tucker, J., & Czajkowski, F. (2001) · Journal of Clinical Pharmacy and Therapeutics · doi:10.1046/j.1365-2710.2001.00326.x · Cited by 13
Craving: concepto, medición y terapéutica
Castillo, I. I., & Bilbao, N. C. (2008) · Dialnet (Universidad de la Rioja) · Cited by 13
Disulfiram induced psychosis: Revisiting an age-old entity
Das, N., Mahapatra, A., & Sarkar, S. (2017) · Asian Journal of Psychiatry · doi:10.1016/j.ajp.2017.08.011 · Cited by 13
Alcohol liver disease: A review of current therapeutic approaches to achieve long-term abstinence
García, M. L. G. (2015) · World Journal of Gastroenterology · doi:10.3748/wjg.v21.i28.8516 · Cited by 13
EFFECT OF COMMUNITY NURSE FOLLOW-UP WHEN TREATING ALCOHOL DEPENDENCE WITH ACAMPROSATE
Pelc, I., Hanak, C., Baert, I., HOUTAIN, C., Lehert, P., Landron, F., & Verbanck, P. (2005) · Alcohol and Alcoholism · doi:10.1093/alcalc/agh136 · Cited by 14
“In addition, pharmacotherapy is also useful, particularly, naltrexone and acamprosate (Garbutt et al., 1999).”
Background
Sustained-Release Naltrexone Formulations for the Treatment of Alcohol and Opioid Dependence
Volpicelli, J. R., & Fenton, M. C. (2006) · Future Neurology · doi:10.2217/14796708.1.4.389 · Cited by 14
“Acamprosate is thought to improve abstinence rates in alcoholdependent subjects by reducing neuroexcitation at the N-methyl-D-aspartic acid receptor, which accompanies alcohol withdrawal [8–10].”
Background
Replicating the Addicted-Self Model of recovery.
Fiorentine, R., & Hillhouse, M. P. (2003) · Addictive Behaviours · doi:10.1016/s0306-4603(02)00231-9 · Cited by 13
Neurobiology of Alcoholism
Soyka, M., & Schütz, C. (2001) · CRC Press eBooks · doi:10.3109/9780203902172-11 · Cited by 13
Alcoholic Hepatitis
Agarwal, K., Kontorinis, N., & Dieterich, D. T. (2004) · Current Treatment Options in Gastroenterology · doi:10.1007/s11938-004-0004-6 · Cited by 13
Multidimensional alcoholism typologies: could they guide clinical practice? Results from a 3-month prospective study
Pombo›, S., da Costa, N. F., Figueira, M. L., Ismail, F., & Lesch, O. (2015) · International Journal of Psychiatry in Clinical Practice · doi:10.3109/13651501.2015.1016972 · Cited by 12
“Other medications were only prescribed if psychiatric symptoms persisted (Garbutt et al. 1999).”
Background
Understanding and Treating Alcohol Dependence
Johnson, B. A., Koob, G. F., Schuckit, M. A., Mason, B. J., & Ait‐Daoud, N. (2006) · Alcoholism Clinical and Experimental Research · doi:10.1111/j.1530-0277.2005.00066.x · Cited by 12
Exploration of Core Symptoms for the Diagnosis of Alcohol Dependence in the ICD‐10
Yoshimura, A., Komoto, Y., & Higuchi, S. (2016) · Alcoholism Clinical and Experimental Research · doi:10.1111/acer.13225 · Cited by 12
“Recently, anticraving drugs, such as naltrexone and nalmefene, have been shown to be effective for the reduction of drinking and the maintenance of abstinence in the pharmacological treatment of alcohol use disorder (Garbutt et al., 1999; O’Brien, 2005; Paille and Martini, 2014).”
Background
A pilot study comparing in-person and web-based motivational interviewing among adults with a first-time DUI offense
Osilla, K. C., Paddock, S. M., Leininger, T. J., D’Amico, E. J., Ewing, B. A., & Watkins, K. E. (2015) · Addiction Science & Clinical Practice · doi:10.1186/s13722-015-0039-0 · Cited by 11
“If dependence rates are similarly high in other programs, more intensive treatment approaches such as cognitive behavioral therapy or medication-assisted therapy may be more effective [53–58].”
Background
Suchtkranke Rechtsbrecher
Schalast, N. (2006) · Steinkopff eBooks · doi:10.1007/3-7985-1633-2_12 · Cited by 11
A Double-Blind, Placebo-Controlled Study of Naltrexone in the Treatment of Alcohol-Dependence Disorder: Results from a Multicenter Clinical Trial
Guardia, J., Caso, C., Árias, F., Gual, A., Sanahuja, J., rez, M. R., Mengual, I., Gonzalvo, B. A., Segura, L., Trujols, J., et al. (2002) · Alcoholism Clinical and Experimental Research · doi:10.1097/00000374-200209000-00011 · Cited by 12
Current concepts in pharmacotherapy of substance abuse
Gottschalk, P., Jacobsen, L. K., & Kosten, T. R. (1999) · Current Psychiatry Reports · doi:10.1007/s11920-999-0028-7 · Cited by 11
Pharmacotherapy for relapse prevention of alcohol use disorder in the Indian setting: A systematic review
Bharadwaj, B., Selvakumar, N., & Kuppili, P. P. (2018) · Industrial Psychiatry Journal · doi:10.4103/ipj.ipj_79_17 · Cited by 10
“[29] However, several studies have documented the better evidence base for acamprosate or naltrexone when compared to disulfiram in the Western setting.[30] An important issue worth critically appraising is that these results were not replicated in blinded trials.”
Result
Medical Students' Knowledge About Alcohol and Drug Problems
Kahan, M., Midmer, D., Wilson, L., & Borsoi, D. (2007) · Substance Abuse · doi:10.1300/j465v27n04_01 · Cited by 10
“27(4) 2006 Available online at http://suba.”
Background
Naltrexone and Pharmacy Benefit Management
Harris, K. M., & Thomas, C. P. (2004) · Journal of Addictive Diseases · doi:10.1300/j069v23n04_02 · Cited by 10
“These factors include (1) a physician work force that is not generally trained to recognize and treat alcohol problems, (2) the dominance of psychosocial and self-help/mutual aid treatment models, such as Alcoholics Anonymous, operating outside of formal physician referral networks that complicate the integration of p…”
Background
Acamprosate: a new tool in the battle against alcohol dependence
Wright, T. M., & Myrick, H. (2006) · Neuropsychiatric Disease and Treatment · doi:10.2147/nedt.2006.2.4.445 · Cited by 11
The costs of alcoholism
Simon, J., Patel, A. K., & Sleed, M. (2005) · Journal of Mental Health · doi:10.1080/09638230500195130 · Cited by 10
Acamprosate
Foster, R. H., & McClellan, K. J. (1999) · PharmacoEconomics · doi:10.2165/00019053-199916060-00010 · Cited by 10
Does the Intake of Ethanol Affect Oral Absorption of Poorly Soluble Drugs?
Keemink, J., Sjögren, E., Holm, R., & Bergström, C. A. S. (2018) · Journal of Pharmaceutical Sciences · doi:10.1016/j.xphs.2018.12.006 · Cited by 10
Oral operant ethanol self-administration in the absence of explicit cues, food restriction, water restriction and ethanol fading in C57BL/6J mice
Stafford, A. M., Anderson, S. M., Shelton, K. L., & Brunzell, D. H. (2015) · Psychopharmacology · doi:10.1007/s00213-015-4040-9 · Cited by 9
Pharmacoprophylaxis of alcohol dependence: Review and update Part II: Efficacy
Grover, S., Basu, D., & Bhateja, G. (2007) · Indian Journal of Psychiatry · doi:10.4103/0019-5545.31515 · Cited by 9
Management of Alcohol Abuse
Albanese, A. P. (2012) · Clinics in Liver Disease · doi:10.1016/j.cld.2012.08.006 · Cited by 9
Atención y craving o ganas compulsivas. Avances en su conceptualización y su implicación en la prevención de recaídas
Blasco, J., Martı́nez-Raga, J., Carrasco, E., & Didia-Attas, J. (2008) · Adicciones · doi:10.20882/adicciones.259 · Cited by 9
Long-acting injectable depot naltrexone use in the Veterans' Health Administration: A national study
Marienfeld, C. B., Iheanacho, T., Issa, M. A., & Rosenheck, R. A. (2013) · Addictive Behaviors · doi:10.1016/j.addbeh.2013.05.006 · Cited by 8
Pharmakologische Rückfallprävention bei Alkohol- und Tabakabhängigkeit
Diehl, A., & Mann, K. F. (2006) · Der Internist · doi:10.1007/s00108-006-1755-z · Cited by 8
The effects of calorie restriction on operant-responding for alcohol in the alcohol preferring (iP) rat
Guccione, L., Paolini, A. G., Penman, J., & Djouma, E. (2012) · Behavioural Brain Research · doi:10.1016/j.bbr.2012.02.015 · Cited by 8
What Is Evidence-Based Treatment?
Sorensen, J. L., Hettema, J. E., & Larios, S. E. (2009) · Elsevier eBooks · doi:10.1016/b978-0-12-374348-0.00001-x · Cited by 9
Carbohydrates, Alcohols, and Organic Acids
Kohlmeier, M. (2015) · Elsevier eBooks · doi:10.1016/b978-0-12-387784-0.00006-7 · Cited by 7
NALTREXONE IN THE TREATMENT OF ALCOHOL DEPENDENCE
Rystal, J. O. H. K., Oyce, J., Ramer, A. C., Rol, W. I. F. K., Irk, G. A. F. K., & Osenheck, R. O. A. R. (2001) · Cited by 8
Opioid Antagonists and Alcoholism Treatment
Swift, R. M. (2000) · CNS Spectrums · doi:10.1017/s1092852900012815 · Cited by 8
Commentary: Doxasozin for Alcoholism
Leggio, L., & Kenna, G. A. (2012) · Alcoholism Clinical and Experimental Research · doi:10.1111/acer.12064 · Cited by 8
“In fact, an important factor that has thus far limited the effectiveness of medications for AD patients is poor adherence to medication regimens (Garbutt et al., 1999; Weiss, 2004).”
Increasing access to psychosocial interventions for alcohol use disorders: Home based interventions
Nadkarni, A. (2018) · Indian Journal of Psychiatry · doi:10.4103/psychiatry.indianjpsychiatry_25_18 · Cited by 7
Le disulfirame (Esperal®) dans le traitement des addictions : rappels et nouvelles perspectives d’utilisation
Charpeaud, T., Geneste, J., Schmidt, J., Llorca, P., & Brousse, G. (2011) · Therapies · doi:10.2515/therapie/2011025 · Cited by 7
A multiple schedule model of limited access drinking in the cynomolgus macaque
Shelton, K. L., Young, J. E., & Grant, K. A. (2001) · Behavioural Pharmacology · doi:10.1097/00008877-200112000-00001 · Cited by 7
Online mutual-help intervention for reducing heavy alcohol use
Haug, N. A., Morimoto, E. E., & Lembke, A. (2020) · Journal of Addictive Diseases · doi:10.1080/10550887.2020.1747331 · Cited by 7
Trust, performance management and the new GP contract.
Maynard, A., & Bloor, K. E. (2003) · Europe PMC (PubMed Central) · Cited by 7
Update in Addiction Medicine
Schneider, R. K., Levenson, J. L., & Schnoll, S. H. (2001) · Annals of Internal Medicine · doi:10.7326/0003-4819-134-5-200103060-00011 · Cited by 7
“Much recent research has centered on effective pharmacologic management (after detoxification) of alcoholism, recently reviewed by Garbutt and colleagues (2).”
Background
Improving the Quality of Substance Dependency Treatment with Pharmacotherapy
Boyarsky, B. K., & McCance‐Katz, E. F. (2000) · Substance Use & Misuse · doi:10.3109/10826080009148251 · Cited by 7
Evidence base to a preventive health assessment in Aboriginal and Torres Strait Islander peoples
Couzos, S., & Consultants Chronic Disease Alliance (2005) · ResearchOnline - JCU (James Cook University) · Cited by 7
Substance‐Related Disorders: Alcohol‐Related Disorders
Babor, T. F., Hernandez‐Avila, C. A., & Ungemack, J. A. (2015) · Psychiatry · doi:10.1002/9781118753378.ch72 · Cited by 8
Treatment of Decompensated Alcoholic Liver Disease
Menachery, J., & Duseja, A. K. (2011) · International Journal of Hepatology · doi:10.4061/2011/219238 · Cited by 6
“Both acamprosate and naltrexone have been demonstrated to reduce the number of drinking days and increase abstinence rates in randomized controlled trials [19].”
Background
Pharmacology of Geriatric Substance Use Disorders: Considerations and Future Directions
Hassell, C., Wilkins, K. M., & Trevisan, L. (2017) · Current Treatment Options in Psychiatry · doi:10.1007/s40501-017-0107-z · Cited by 6
The Dopamine System in Mediating Alcohol Effects in Humans
Beck, A., Ebrahimi, C., Rosenthal, A., Charlet, K., & Heinz, A. (2023) · Current topics in behavioral neurosciences · doi:10.1007/7854_2022_415 · Cited by 9
Nonclinical Pharmacology of VIVITROL®: A Monthly Injectable Naltrexone for the Treatment of Alcohol Dependence
Dean, R. L. (2009) · Humana Press eBooks · doi:10.1007/978-1-59745-197-0_35 · Cited by 6
Substance abuse treatment, what do we know? An economist's perspective.
Machado, M. P. (2005) · PubMed · doi:10.1007/s10198-004-0253-2
“One strategy is to use medication to treat substance abuse (for a review see [20]).”
Background
NHG-Standaard Problematisch alcoholgebruik
Meerkerk, G., Aarns, T., Dijkstra, R. H., Weisscher, P., Njoo, K. H., & Boomsma, L. (2011) · Bohn Stafleu van Loghum eBooks · doi:10.1007/978-90-313-8279-8_50 · Cited by 6
A case of marked ST depression and myocardial injury as a result of disulfiram–ethanol reaction
Shioji, K., Izuhara, M., Kadota, S., Baba, O., Mitsuoka, H., Uegaito, T., & Matsuda, M. (2009) · Journal of Cardiology Cases · doi:10.1016/j.jccase.2009.11.002 · Cited by 5
“Disulfiram is an irreversible inhibitor of aldehyde dehydrogenase (ALDH) recommended in the treatment of alcohol dependency disorders to prevent drinking [1—3].”
Background
Alcohol Biomarkers
Bornhorst, J. A., & Mbughuni, M. M. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-815607-0.00003-4 · Cited by 5
Neurobiology of Addiction
Sebold, M., Garbusow, M., Müller, C. A., Charlet, K., & Heinz, A. (2014) · Springer eBooks · doi:10.1007/978-88-470-5322-9_2 · Cited by 6
Acamprosate: clinical data
Mann, K. F. (2006) · Birkhäuser-Verlag eBooks · doi:10.1007/3-7643-7305-9_8 · Cited by 5
“In the systematic review of Garbutt, which analysed all data available up to 1997 [ 23 ], it was concluded that the proof of efficacy for acamprosate was strong, with the most consistent finding being a decrease in drinking frequency, with several studies reporting abstinence rates to be doubled.”
Background
Alcoholic Liver Disease
Stewart, S. F., & Day, C. P. (2006) · Elsevier eBooks · doi:10.1016/b978-1-4160-3258-8.50034-6 · Cited by 5
Thyroid Function of Former Opioid Addicts on Naltrexone Treatment
Ilias, Ι., Kakoulas, I., Christakopoulou, I., & Katsadoros, K. (2001) · Acta Medica (Hradec Kralove Czech Republic) · doi:10.14712/18059694.2019.84 · Cited by 5
“as a non-addicting, long-acting adjunctive medication for the treatment of detoxified opiate addicts (15) and alcohol dependence (6).”
Background
Toxicology of Specific Substances
Jones, A. W., Mußhoff, F., Kræmer, T., Steuer, A. E., Gerostamoulos, D., Drummer, O. H., Drasch, G. A., Balı́ková, M., Beyer, J., Teixeira, H. M., et al. (2014) · doi:10.1002/9781118570654.ch51 · Cited by 5
Brief Interventions for Problem Drinking: Another Piece of the Puzzle
O’Connor, P. G. (2007) · Annals of Internal Medicine · doi:10.7326/0003-4819-146-3-200702060-00012 · Cited by 5
“Alcohol-dependent inpatients may need more intensive treatment that could include specific counseling strategies (17) and pharmacologic therapies (18), which are shown to be effective in alcohol-dependent patients.”
Background
Utilización de naltrexona en el tratamiento del alcoholismo en España
Rubio, G., Martínez, F., Fortea, M. S., & de Laguna, J. L. B. G. (2002) · Revista Clínica Española · doi:10.1016/s0014-2565(02)71103-x · Cited by 5
Pharmacologic Interventions for Pregnant Women Enrolled in Alcohol Treatment
Smith, E. J., Terplan, M., & Lui, S. (2008) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd007361 · Cited by 5
Long-Term Excessive Alcohol Consumption Enhances Myelination in the Mouse Nucleus Accumbens
Liran, M., Fischer, I., Elboim, M., Rahamim, N., Gordon, T., Urshansky, N., Assaf, Y., Barak, B., & Barak, S. (2025) · Journal of Neuroscience · doi:10.1523/jneurosci.0280-24.2025 · Cited by 4
“Nevertheless, pharmacological treatment is currently highly limited (Garbutt et al., 1999; Witkiewitz et al., 2019).”
Alcoholism: The Self-Reinforcing Feedback Loop
Dorrian, J. (2012) · InTech eBooks · doi:10.5772/31626 · Cited by 4
Treatment of Alcoholic Liver Disease Including Emerging Therapies, Novel Targets, and Liver Transplantation
Petrášek, J., & Szabó, G. (2015) · Springer eBooks · doi:10.1007/978-3-319-20538-0_15 · Cited by 4
Pharmacological Treatment of Substance Use Disorders
Srivastava, A. B., LEVIN, F. R., & Nunes, E. V. (2023) · Springer eBooks · doi:10.1007/978-3-030-42825-9_140-1 · Cited by 4
Alcoholism and Substance Abuse
Warne, D. K. (2017) · Elsevier eBooks · doi:10.1016/b978-0-323-35868-2.00083-9 · Cited by 4
Evidence-based treatments in liaison psychiatry
Ruddy, R., & House, A. O. (2006) · Psychiatry · doi:10.1383/psyt.2006.5.3.102 · Cited by 4
A new polyamine derivative, a structural analog of spermine, with in vivo activity as an inhibitor of ethanol appetite
Font, M., Sanmartín, C., García, H., Contreras, S., Paeile, C., & Bilbeny, N. (2005) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2005.04.067 · Cited by 4
Efficacy of Dexfenfluramine in the Treatment of Alcohol Dependence
Romach, M. K., Sellers, E. M., Kaplan, H. L., Somer, G. R., & Gomez‐Mancilla, B. (2000) · Alcoholism Clinical and Experimental Research · doi:10.1097/00000374-200010000-00011 · Cited by 4
Community participation and mental health prior to treatment
McGaffin, B., Deane, F., & Kelly, P. (2017) · Advances in Dual Diagnosis · doi:10.1108/add-10-2016-0017 · Cited by 4
When low self-efficacy is efficacious: toward an addicted-self model of cessation of alcohol- and drug-dependent behavior.
Fiorentine, R., & Hillhouse, M. P. (2003) · American Journal on Addictions · doi:10.1111/j.1521-0391.2003.tb00549.x · Cited by 36
Novel pharmacotherapies and patents for alcohol abuse and alcoholism 1998-2001
Agabio, R., Colombo, G., Carai, M. A. M., & Gessa, G. L. (2001) · Expert Opinion on Therapeutic Patents · doi:10.1517/13543776.11.10.1497 · Cited by 4
Psychische Störungen und Verhaltensstörungen durch psychotrope Substanzen
Fehr, C., Szegedi, A., Scherbaum, N., Davids, E., Gastpar, M., Leweke, F. M., Hoyer, C., Gouzoulis‐Mayfrank, E., & Lorscheider, M. (2008) · Springer eBooks · doi:10.1007/978-3-540-68748-1_40 · Cited by 4

Authors: Garbutt, J. C., West, S. L., Carey, T. S., Lohr, K. N., & Crews, F. T.
Affiliations: University of North Carolina at Chapel Hill (US)
RTI International (US)
ORCID: West, Suzanne L.
Carey, Timothy S.
Lohr, Kathleen N.
Crews, Fulton T.
Venue: JAMA
Publisher: American Medical Association (AMA)
Published: 1999-04-14
Volume: 281
Issue: 14
Pages: 1318
ISSN: 0002-9955 (ISSN-L)
0098-7484
DOI: 10.1001/jama.281.14.1318
OpenAlex: W2082518171
Cited by: 444
References: 43
Citations by year: 2025: 3 · 2024: 3 · 2023: 4 · 2022: 6 · 2021: 3 · 2020: 11 · 2019: 13 · 2018: 12 · 2017: 13 · 2016: 11 · 2015: 17 · 2014: 13 · 2013: 15 · 2012: 19
FWCI: 21.16
Type: journal article
Language: en
Open access: closed
Locations: JAMA (publishedVersion)
PubMed (publishedVersion)
Funders: U.S. Public Health Service (290-97-0011)
Topics: Health Sciences › Medicine › Epidemiology › Substance Abuse Treatment and Outcomes
Health Sciences › Medicine › Pathology and Forensic Medicine › Alcohol Consumption and Health Effects
Health Sciences › Medicine › Clinical Neurology › Alcoholism and Thiamine Deficiency
Keywords: alcoholism, pharmacotherapy, disulfiram, naltrexone, nalmefene, acamprosate, selective serotonin reuptake inhibitors, lithium, relapse prevention, abstinence, drinking frequency, craving, treatment efficacy, quality of evidence grading, psychosocial interventions
MeSH terms: Acamprosate, Adult, Alcohol Deterrents, Alcoholism, Disulfiram, Humans, Lithium, Naltrexone, Narcotic Antagonists, Taurine, Serotonin Agents

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Pharmacological Treatment of Alcohol Dependence: A Review of the Evidence

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks